Log in

NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

$94.29
-2.64 (-2.72 %)
(As of 02/26/2020 02:30 AM ET)
Today's Range
$93.50
Now: $94.29
$98.44
50-Day Range
$94.29
MA: $104.21
$113.76
52-Week Range
$71.85
Now: $94.29
$119.65
Volume690,749 shs
Average Volume761,032 shs
Market Capitalization$8.70 billion
P/E Ratio285.73
Dividend YieldN/A
Beta1.53
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.62 per share
Book Value$6.92 per share

Profitability

Net Income$37.01 million

Miscellaneous

Employees585
Market Cap$8.70 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Tuesday, February, 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $0.40. The firm earned $244.10 million during the quarter, compared to the consensus estimate of $231.54 million. Neurocrine Biosciences had a net margin of 4.70% and a return on equity of 8.27%. The business's revenue was up 85.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.19 EPS. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

15 brokers have issued 1-year price objectives for Neurocrine Biosciences' stock. Their forecasts range from $88.00 to $153.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $116.92 in the next year. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Has Neurocrine Biosciences been receiving favorable news coverage?

News headlines about NBIX stock have trended very positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news impact score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Neurocrine Biosciences.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,240,000 shares, a decline of 8.4% from the December 31st total of 4,630,000 shares. Based on an average trading volume of 936,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 4.7% of the company's shares are sold short. View Neurocrine Biosciences' Current Options Chain.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Twilio (TWLO), Exelixis (EXEL), salesforce.com (CRM) and Vertex Pharmaceuticals (VRTX).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (7.99%), Capital International Investors (6.32%), Perceptive Advisors LLC (3.91%), Perceptive Advisors LLC (3.91%), Alliancebernstein L.P. (1.34%) and Geode Capital Management LLC (1.12%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Institutional Ownership Trends for Neurocrine Biosciences.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Janus Henderson Group PLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P. and First Trust Advisors LP. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and Matt Abernethy. View Insider Buying and Selling for Neurocrine Biosciences.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, 1832 Asset Management L.P., Swiss National Bank and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $94.29.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $8.70 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  841 (Vote Outperform)
Underperform Votes:  297 (Vote Underperform)
Total Votes:  1,138
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel